Effects of Gallium on Bone in the Rat
Open Access
- 1 January 1992
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 7 (1) , 11-19
- https://doi.org/10.1002/jbmr.5650070104
Abstract
Gallium nitrate lowers the serum calcium in patients with hypercalcemia caused by malignancy and is available for clinical use. The mechanism for the hypocalcemic action is unknown, however. The present studies were undertaken to determine the effects of gallium on bone metabolism. Normal male rats were implanted subcutaneously with mineralized allogeneic bone matrix. Histomorphometry of the implants and of tibiae was determined after three doses of tetracycline administered at intervals of 1 week. Gallium as nitrate was administered daily by intraperitoneal injection at doses of 0.9, 1.8, and 3.6 mg elemental gallium per kg body weight for 21 days in one study and at 3.5 mg/kg for 33 days in a second study. All the gallium-treated rats gained weight. Rats given gallium at doses of 3.5 mg/kg or more grew at a lower rate than untreated controls (-7 and -10% at doses of 3.5 and 3.6 mg/kg, respectively; p < 0.05). At a dose of 0.9 mg/kg, gallium did not inhibit bone resorption or lower serum calcium but inhibited bone formation by 32% and bone apposition by 36% at the endosteal surface of the tibia. At a dose of 1.8 mg/kg, gallium produced modest hypocalcemia, prevented a rise in circulating 1,25-dihydroxyvitamin D [1,25-(OH)2D], inhibited bone resorption in implants, and inhibited bone formation by 19% and bone apposition by 18%. At a dose of 3.5 mg/kg, gallium lowered the serum calcium and serum 1,25-(OH)2D, inhibited growth, and accentuated the antiresorptive and antiformative effects seen at the two lower doses. The results indicate that gallium inhibits bone resorption, produces hypocalcemia, alters vitamin D metabolism, and inhibits bone formation at doses below those that inhibit bone resorption. The mechanism for hypocalcemia may be by direct action on bone and could involve an indirect effect on calcium metabolism mediated by changes in the metabolism of vitamin D.Funding Information
- National Institutes of Health (AM33025)
- Loma Linda University School of Medicine
- Department of Orthopaedic Surgery of Lima Linda University
This publication has 26 references indexed in Scilit:
- Gallium inhibits bone resorption by a direct effect on osteoclastsBone and Mineral, 1990
- Use of gallium to treat Paget's disease of bone: a pilot studyThe Lancet, 1990
- Effect of gallium on thein vitro formation, growth, and solubility of hydroxyapatiteCalcified Tissue International, 1989
- Effect of gallium on bone mineral propertiesCalcified Tissue International, 1988
- Osteoinduction by implants of demineralized allogeneic bone matrix is diminished in vitamin D-deficient ratsCalcified Tissue International, 1988
- Bone modeling in gallium nitrate-treated ratsCalcified Tissue International, 1987
- Gallium increases bone calcium and crystallite perfection of hydroxyapatiteCalcified Tissue International, 1986
- Parenteral aluminum administration in the dog: II. Induction of osteomalacia and effect on vitamin D metabolismKidney International, 1984
- Demonstration of a lack of change in serum 1 alpha,25-dihydroxyvitamin D in response to parathyroid extract in pseudohypoparathyroidism.Journal of Clinical Investigation, 1980
- Evidence that Increased Circulating 1α,25-Dihydroxyvitamin D is the Probable Cause for Abnormal Calcium Metabolism in SarcoidosisJournal of Clinical Investigation, 1979